

# Tomas Jelinek

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5013629/publications.pdf>

Version: 2024-02-01

44  
papers

950  
citations

567281

15  
h-index

477307

29  
g-index

44  
all docs

44  
docs citations

44  
times ranked

1922  
citing authors

#	ARTICLE	IF	CITATIONS
1	Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. <i>Leukemia</i> , 2022, 36, 288-291.	7.2	23
2	FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology. <i>Blood Advances</i> , 2022, 6, 690-703.	5.2	19
3	Natural killer cells: Innate immune system as a part of adaptive immunotherapy in hematological malignancies. <i>American Journal of Hematology</i> , 2022, , .	4.1	2
4	Management of Treatment-Related Infectious Complications in High-Risk Hemato-Oncological Patients via Telemedicine. <i>Cancer Management and Research</i> , 2022, Volume 14, 1655-1661.	1.9	2
5	Focus on monoclonal antibodies targeting Bâ€œell maturation antigen (BCMA) in multiple myeloma: update 2021. <i>British Journal of Haematology</i> , 2021, 193, 705-722.	2.5	18
6	Selinexor, selective inhibitor of nuclear export: Unselective bullet for blood cancers. <i>Blood Reviews</i> , 2021, 46, 100758.	5.7	8
7	Selection, Expansion, and Unique Pretreatment of Allogeneic Human Natural Killer Cells with Anti-CD38 Monoclonal Antibody for Efficient Multiple Myeloma Treatment. <i>Cells</i> , 2021, 10, 967.	4.1	9
8	Bortezomibâ€œbased therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data. <i>European Journal of Haematology</i> , 2021, 107, 466-474.	2.2	1
9	Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies. <i>Frontiers in Pharmacology</i> , 2021, 12, 733890.	3.5	9
10	Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia. <i>British Journal of Haematology</i> , 2021, 195, 95-107.	2.5	6
11	Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine. <i>Blood Advances</i> , 2021, , .	5.2	3
12	Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11470.	4.1	6
13	Identification of patients at high risk of secondary extramedullary multiple myeloma development. <i>British Journal of Haematology</i> , 2021, , .	2.5	8
14	Circulating Tumor Cells (CTCs) in Smoldering and Active Multiple Myeloma (MM): Mechanism of Egression, Clinical Significance and Therapeutic Endpoints. <i>Blood</i> , 2021, 138, 76-76.	1.4	7
15	Follow-up Analysis of Ixazomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Routine Clinical Practice. <i>Blood</i> , 2021, 138, 2716-2716.	1.4	1
16	Effect of Daratumumab-Containing Induction on CD34+ Hematopoietic Stem Cells before Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , 2021, 138, 2764-2764.	1.4	1
17	Natural Killer Cells in the Malignant Niche of Multiple Myeloma. <i>Frontiers in Immunology</i> , 2021, 12, 816499.	4.8	14
18	Dynamics of tumorâ€œspecific cfDNA in response to therapy in multiple myeloma patients. <i>European Journal of Haematology</i> , 2020, 104, 190-197.	2.2	23

#	ARTICLE	IF	CITATIONS
19	A Bird's-Eye View of Cell Sources for Cell-Based Therapies in Blood Cancers. <i>Cancers</i> , 2020, 12, 1333.	3.7	9
20	Intercellular Mitochondrial Transfer in the Tumor Microenvironment. <i>Cancers</i> , 2020, 12, 1787.	3.7	25
21	Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma. <i>Expert Review of Hematology</i> , 2020, 13, 375-392.	2.2	5
22	Monoclonal antibodies in the treatment of AL amyloidosis: co-targeting the plasma cell clone and amyloid deposits. <i>British Journal of Haematology</i> , 2020, 189, 228-238.	2.5	19
23	Venetoclax: the first anti-myeloma agent with a reliable biomarker. <i>British Journal of Haematology</i> , 2020, 189, 1003-1005.	2.5	6
24	Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1049-1061.	1.8	31
25	Venetoclax plus bortezomib and dexamethasone in heavily pretreated end-stage myeloma patients without t(11;14): A real-world cohort. <i>Hematological Oncology</i> , 2020, 38, 412-414.	1.7	11
26	Identification of Molecular Mechanisms Responsible for the Development of Extramedullary Disease in Myeloma and Potential Novel Therapeutic Targets Using Transcriptomic and Exome Profiling. <i>Blood</i> , 2020, 136, 16-17.	1.4	0
27	Identification of Novel Regulatory Pathway for Immunoglobulin Production Provides Rational Treatment for Bortezomib-Resistant Multiple Myeloma Patients. <i>Blood</i> , 2020, 136, 40-42.	1.4	0
28	The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2019, 25, 3176-3187.	7.0	156
29	Extramedullary disease in multiple myeloma – controversies and future directions. <i>Blood Reviews</i> , 2019, 36, 32-39.	5.7	66
30	Cytarabine+G-CSF is more effective than cyclophosphamide+G-CSF as a stem cell mobilization regimen in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 1107-1114.	2.45	10
31	Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14). <i>American Journal of Hematology</i> , 2019, 94, E35-E37.	4.1	35
32	Overall Survival Benefit of Ixazomib, Lenalidomide and Dexamethasone (IRD) over Lenalidomide and Dexamethasone (RD) in RRMM Patients Treated in Routine Clinical Practice: Results from the Czech Registry of Monoclonal Gammopathies (RMG). <i>Blood</i> , 2019, 134, 3139-3139.	1.4	2
33	Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population. <i>Biomedical Papers of the Medical Faculty of the University Palacky&amp;#x0301;, Olomouc, Czechoslovakia</i> , 2019, 163, 279-283.	0.6	10
34	Venetoclax: A new wave in hematooncology. <i>Experimental Hematology</i> , 2018, 61, 10-25.	0.4	73
35	Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients. <i>Current Medical Research and Opinion</i> , 2018, 34, 775-783.	1.9	11
36	Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma. <i>Frontiers in Immunology</i> , 2018, 9, 2431.	4.8	85

#	ARTICLE	IF	CITATIONS
37	Treatment of Relapsed and Refractory Multiple Myeloma with Fully Oral Triplet IRD (ixazomib,) Tj ETQq1 1 0.784314 rgBT /Overlock 101 1959-1959.	1.4	4
38	CD38-targeted treatment for multiple myeloma. Vnitřní Lekarství, 2018, 64, 939-948.	0.2	3
39	PD-1 inhibitors in haematological malignancies: update 2017. Immunology, 2017, 152, 357-371.	4.4	108
40	Cytogenetics in multiple myeloma patients progressing into extramedullary disease. European Journal of Haematology, 2016, 97, 93-100.	2.2	37
41	Monoclonal antibodies – A new era in the treatment of multiple myeloma. Blood Reviews, 2016, 30, 101-110.	5.7	43
42	Comparative Effectiveness of Daratumumab Monotherapy Versus a Real-World Historical Control from the Czech Republic in Heavily Pretreated and Highly Refractory Multiple Myeloma Patients. Blood, 2016, 128, 3332-3332.	1.4	1
43	Identification of Phenotype Profile Related to the Extramedullary Involvement in Multiple Myeloma Relapse. Blood, 2016, 128, 5653-5653.	1.4	3
44	Plasma cell leukemia: from biology to treatment. European Journal of Haematology, 2015, 95, 16-26.	2.2	37